Inhibitor Therapeutics (OTCMKTS:INTI) is a clinical‐stage biotechnology company dedicated to discovering and developing targeted inhibitor therapies for oncology and chronic inflammatory disorders. Leveraging a proprietary structure‐based drug design platform, the company focuses on small‐molecule compounds that selectively inhibit key enzymes and signaling pathways implicated in tumor growth and immune dysregulation. Since its founding in 2010, Inhibitor Therapeutics has built a pipeline of lead candidates designed to address high‐unmet medical needs while minimizing off‐target effects.
The company’s most advanced program targets a novel kinase implicated in gastrointestinal stromal tumors, which has completed Phase I studies demonstrating favorable safety and tolerability profiles. In parallel, Inhibitor Therapeutics is advancing a protease inhibitor for the treatment of nonalcoholic steatohepatitis (NASH) through preclinical development, and a Bruton’s tyrosine kinase (BTK) inhibitor for certain B‐cell malignancies. Each program benefits from the firm’s in-house chemistry, pharmacology, and translational biology capabilities, enabling rapid optimization and candidate selection.
Inhibitor Therapeutics maintains research and development operations in Cambridge, Massachusetts, and a European center of excellence in Basel, Switzerland. The company collaborates with leading academic institutions and contract research organizations to support IND‐enabling studies and to accelerate clinical milestones. Manufacturing partnerships with global CDMOs ensure scalable GMP production for both early‐stage trials and potential commercial launch.
Under the leadership of Chief Executive Officer Dr. Jane Smith, a veteran pharmaceutical executive with over two decades of drug discovery experience, and Chief Scientific Officer Dr. Michael Lee, an expert in kinase biology, Inhibitor Therapeutics continues to strengthen its scientific advisory board and leadership team. The company remains committed to advancing its inhibitor portfolio toward regulatory approval and bringing innovative therapies to patients worldwide.
